Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12983640 | 1.00 | NOS3 (0.35) | NOS3NOS1NOS2DRD2DRD1 | |
| SCHEMBL20482614 | 0.89 | CXCR4 (0.39) | NOS3NOS1NOS2CXCR4FNTA | |
| SCHEMBL6669137 | 0.89 | CXCR4 (0.39) | NOS3NOS1NOS2CXCR4FNTA | |
| Hydrochloric Acid SCHEMBL11854967 | 0.88 | CXCR4 (0.38) | NOS3NOS1NOS2CXCR4FNTA | |
| Hydrochloric Acid SCHEMBL11853601 | 0.88 | CXCR4 (0.38) | NOS3NOS1NOS2CXCR4FNTA | |
| SCHEMBL10238793 | 0.79 | DRD2 (0.34) | NOS3NOS1NOS2DRD2DRD1 | |
| SCHEMBL23937987 | 0.78 | DRD2 (0.36) | NOS3NOS1NOS2DRD2DRD1 | |
| SCHEMBL14616893 | 0.78 | HTT (0.35) | FNTAFNTB | |
| SCHEMBL12611750 | 0.78 | BACE1 (0.38) | PLAU | |
| SCHEMBL30702209 | 0.78 | HTT (0.35) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742106-B2 | Disubstituted heteroaryl-fused pyridines | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| US-8742106-B2 | Disubstituted heteroaryl-fused pyridines | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| US-8742106-B2 | Disubstituted heteroaryl-fused pyridines | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| EP-2516437-B1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| CN-102762560-A | Disubstituted heteroaryl-fused pyridines | NOVARTIS AG | 2012-10-31 | — | — | CN | disclosed |
| US-20120258973-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-20120258973-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-20120258973-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| WO-2011076744-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258973-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | CYP4F2, CYP11B2, CYP4F3 | NOS3 1372/4885NOS1 1579/4885NOS2 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.